Posts Tagged 'Byetta'

Diabetes drug maker allegedly hid cancer risk

A lawsuit has gone to jury trial in Los Angeles, alleging that the manufacturer of the diabetes drug Actos concealed its cancer risks, Bloomberg reports.

The plaintiff’s lawyer claims that internal studies by Takeda, Asia’s biggest drug manufacturer, uncovered Actos’s links to bladder cancer as early as 2004. But the company didn’t alert U.S. regulators until seven years later, in order to protect more than $1.6 billion in annual sales.

Other diabetes ...

continue reading...

FDA approves new diabetes drug

The U.S. Food and Drug Administration has approved Johnson & Johnson’s drug Invokana, which will be used to treat type 2 diabetes.

According to the New York Times, Invokana is the first of a new class of diabetes medication. It causes blood sugar to be excreted in the urine, as opposed to many other drugs on the market that work by affecting the supply or use of insulin.

Last year, the FDA ...

continue reading...

Market keeping a close eye on new diabetes drug

A story in Forbes says medical professionals and industry analysts are both keeping a close eye on Johnson & Johnson’s Invokana, newly approved by the U.S. Food and Drug Administration. It’s the first to be approved among a new class of medications that treat type 2 diabetes by reducing blood sugar, rather than affecting the supply or use of insulin.

While the drug has the potential to be a blockbuster for ...

continue reading...

Hormone levels may play role in diabetes

Researchers at Brigham and Women’s Hospital in Boston have released a study concluding that low levels of the hormone melatonin may play a role in developing type 2 diabetes, USA Today reports. They found that women with low levels of melatonin at night had twice the risk of developing type 2 diabetes as those with high levels.

America’s seen a skyrocketing rate of diabetes in recent years. Almost 26 million children ...

continue reading...

Investors should be cautious about diabetes drug

A newly approved diabetes drug from Johnson & Johnson may have the potential to be very profitable, given skyrocketing diabetes rates in the Unites States. But a story on the blog Seeking Alpha cautions investors against being too optimistic, given the disappointing results of other diabetes drugs that have gone on the market.

The story mentions GlaxoSmithKline’s Avandia, which has been linked to increased fatalities from heart disease, and is now ...

continue reading...

FDA examines link between diabetes drugs, cancer

The U.S. Food and Drug Administration is examining unpublished findings by a group of academic researchers, which suggest a potential link between newer diabetes drugs and pancreatic cancer.

Among the drugs being investigated are Merck’s Januvia and Bristol-Myers Squibb’s Byetta, Bloomberg reports.

Researchers called for an investigation after publishing an analysis of insurance records in the medical journal JAMA Internal Medicine. That analysis concluded that diabetics hospitalized with pancreatitis were twice as ...

continue reading...
Page 7 of 13 «...56789...»